Taysha Gene Therapies (NASDAQ:TSHA) Receives Buy Rating from Jefferies Financial Group

Jefferies Financial Group reiterated their buy rating on shares of Taysha Gene Therapies (NASDAQ:TSHA - Free Report) in a report released on Tuesday morning, Benzinga reports. Jefferies Financial Group currently has a $8.00 target price on the stock, up from their previous target price of $2.00.

Several other brokerages have also commented on TSHA. Cantor Fitzgerald reaffirmed an overweight rating and issued a $7.00 price objective on shares of Taysha Gene Therapies in a research report on Tuesday, April 30th. JMP Securities reissued a market outperform rating and set a $5.00 price objective on shares of Taysha Gene Therapies in a report on Wednesday, March 20th. Needham & Company LLC restated a buy rating and issued a $7.00 target price on shares of Taysha Gene Therapies in a research note on Thursday, May 2nd. Piper Sandler initiated coverage on shares of Taysha Gene Therapies in a research report on Tuesday, April 9th. They set an overweight rating and a $9.00 target price for the company. Finally, Chardan Capital upped their price target on shares of Taysha Gene Therapies from $5.00 to $7.00 and gave the company a buy rating in a research note on Thursday, March 21st. Nine research analysts have rated the stock with a buy rating, According to data from MarketBeat, the stock has an average rating of Buy and an average price target of $7.00.

Taysha Gene Therapies Stock Performance

Shares of NASDAQ TSHA traded up $0.17 during midday trading on Tuesday, reaching $2.57. The company's stock had a trading volume of 2,701,134 shares, compared to its average volume of 2,425,833. The company has a debt-to-equity ratio of 0.54, a current ratio of 4.08 and a quick ratio of 4.08. The stock has a market capitalization of $480.64 million, a P/E ratio of -4.01 and a beta of 0.37. The firm has a 50 day moving average price of $2.61 and a 200-day moving average price of $2.10. Taysha Gene Therapies has a 12-month low of $0.50 and a 12-month high of $3.89.

Taysha Gene Therapies (NASDAQ:TSHA - Get Free Report) last announced its quarterly earnings data on Tuesday, March 19th. The company reported $0.35 earnings per share (EPS) for the quarter. The business had revenue of $3.60 million during the quarter, compared to the consensus estimate of $4.75 million. As a group, equities analysts predict that Taysha Gene Therapies will post -0.39 earnings per share for the current year.

Institutional Inflows and Outflows

Several institutional investors have recently made changes to their positions in TSHA. Howard Capital Management Inc. purchased a new position in Taysha Gene Therapies during the fourth quarter worth about $25,000. Victory Capital Management Inc. bought a new stake in shares of Taysha Gene Therapies during the 4th quarter valued at about $28,000. Dynamic Technology Lab Private Ltd purchased a new position in shares of Taysha Gene Therapies during the fourth quarter worth about $31,000. China Universal Asset Management Co. Ltd. bought a new position in shares of Taysha Gene Therapies in the fourth quarter worth approximately $38,000. Finally, Lee Financial Co purchased a new stake in Taysha Gene Therapies in the third quarter valued at approximately $63,000. Institutional investors own 77.70% of the company's stock.

Taysha Gene Therapies Company Profile

Taysha Gene Therapies, Inc, a gene therapy company, focuses on developing and commercializing adeno-associated virus-based gene therapies for the treatment of monogenic diseases of the central nervous system. It primarily develops TSHA-120 for the treatment of giant axonal neuropathy; TSHA-102 for the treatment of Rett syndrome; TSHA-121 for the treatment of CLN7 disease; TSHA-118 for the treatment of CLN1 disease; TSHA-105 for the treatment of for SLC13A5 deficiency; TSHA-113 for the treatment of tauopathies; TSHA-106 for the treatment of angelman syndrome; TSHA-114 for the treatment of fragile X syndrome; and TSHA-101 for the treatment of GM2 gangliosidosis.